质子泵抑制剂联合胃动力药治疗咽喉反流性疾病的临床分析
|
摘要
目的探讨奥美拉唑联合莫沙必利治疗咽喉反流性疾病的疗效。方法选取2017年10月至2018年9月来我院就诊的经反流症状指数量表RSI和反流体征指数量表RFS评分诊断为咽喉反流性疾病60例患者。随机分成两组,对照组给予奥美拉唑治疗3个月,观察组在此基础上增加莫沙必利治疗3个月,观察两组治疗的效果。结果对照组(奥美拉唑)有效率为70%,观察组(奥美拉唑+莫沙必利)有效率为90%,两组总有效率比较有差异具有统计学意义(P<0.05)。结论对于咽喉反流性疾病的患者,用奥美拉唑联合莫沙必利治疗优于单一用奥美拉唑,可明显改善LPRD的症状和体征。
Objective To explore the curative effect of omeprazole combined with moxabilli in the treatment of laryngopharyngeal reflux disease. Methods 60 patients who visited our hospital from October 2017 to September 2018 were diagnosed as laryngopharyngeal reflux disease by RSI(reflux symptom index) and RFS(reflux finding score),. They were randomly divided into two groups. The control group was treated with omeprazole for 3 months,and the observation group was added with moxabilli for 3 months. The treatment effect of the two groups was observed.Results The efficiency rate of the control group(omeprazole)was 70%,while that of the observation group(omeprazole + moxabilli)was 90%,and the difference between the two groups was statistically significant(P<0.05). Conclusion For patients with laryngopharyngeal reflux disease,the treatment with omeprazole combined with moxabilli is superior to that with omeprazole alone,which can significantly improve the symptoms and signs of LPRD.
Objective To explore the curative effect of omeprazole combined with moxabilli in the treatment of laryngopharyngeal reflux disease. Methods 60 patients who visited our hospital from October 2017 to September 2018 were diagnosed as laryngopharyngeal reflux disease by RSI(reflux symptom index) and RFS(reflux finding score),. They were randomly divided into two groups. The control group was treated with omeprazole for 3 months,and the observation group was added with moxabilli for 3 months. The treatment effect of the two groups was observed.Results The efficiency rate of the control group(omeprazole)was 70%,while that of the observation group(omeprazole + moxabilli)was 90%,and the difference between the two groups was statistically significant(P<0.05). Conclusion For patients with laryngopharyngeal reflux disease,the treatment with omeprazole combined with moxabilli is superior to that with omeprazole alone,which can significantly improve the symptoms and signs of LPRD.
引文
1.中华耳鼻咽喉头颈外科杂志编辑委员会咽喉组,中华医学会耳鼻咽喉头颈外科学分会咽喉学组.咽喉反流性疾病诊断与治疗专家共识(2015年).中华耳鼻咽喉头颈外科杂志,2016,51:324-326.
2.Tauber S,Gross M,Issing WJ.Association of laryngopharyngeal symptoms with gastroesophageal reflux disease.Laryngoscope,2002,112:879-886.
3.吕芸,何健,卫旭东,等.质子泵抑制剂治疗咽喉反流性疾病的Meta分析.中国耳鼻咽喉头颈外科,2018,25:150-156.
4.张赛,尤乐都斯.阻塞性睡眠呼吸暂停低通气综合征与喉咽反流.国际耳鼻咽喉头颈外科杂志,2014,38:269-272.
5.邬晓力,郭永清.慢性咽炎患者喉咽反流分析.中国耳鼻咽喉头颈外科,2007,14:63-65.
6.Belafsky PC,Postma GN,Koufman JA.Validity and reliability of the reflux symptom index(RSI).Journal of Voice,2002,16:274.
7.Belafsky PC,Postma GN,Koufman JA.The Validity and Reliability of the Reflux Finding Score(RFS).Laryngoscope,2001,111:1313-1317.
8.彭莉莉,李进让,张立红.三位不同职称喉科医师对咽喉反流体征评分量表的应用研究.中华耳鼻咽喉头颈外科杂志,2013,48:461-464.
9.李进让,Belafsky Peter C,张立红.中国喉科医师应用反流体征评分量表的信度研究.中国耳鼻咽喉头颈外科,2012,19:388-390.
10.Campagnolo AM,Priston J,Thoen RH,et al.Laryngopharyngeal reflux:diagnosis,treatment,and latest research.Int Arch Otorhinolaryngol,2014,18:184-191.
2.Tauber S,Gross M,Issing WJ.Association of laryngopharyngeal symptoms with gastroesophageal reflux disease.Laryngoscope,2002,112:879-886.
3.吕芸,何健,卫旭东,等.质子泵抑制剂治疗咽喉反流性疾病的Meta分析.中国耳鼻咽喉头颈外科,2018,25:150-156.
4.张赛,尤乐都斯.阻塞性睡眠呼吸暂停低通气综合征与喉咽反流.国际耳鼻咽喉头颈外科杂志,2014,38:269-272.
5.邬晓力,郭永清.慢性咽炎患者喉咽反流分析.中国耳鼻咽喉头颈外科,2007,14:63-65.
6.Belafsky PC,Postma GN,Koufman JA.Validity and reliability of the reflux symptom index(RSI).Journal of Voice,2002,16:274.
7.Belafsky PC,Postma GN,Koufman JA.The Validity and Reliability of the Reflux Finding Score(RFS).Laryngoscope,2001,111:1313-1317.
8.彭莉莉,李进让,张立红.三位不同职称喉科医师对咽喉反流体征评分量表的应用研究.中华耳鼻咽喉头颈外科杂志,2013,48:461-464.
9.李进让,Belafsky Peter C,张立红.中国喉科医师应用反流体征评分量表的信度研究.中国耳鼻咽喉头颈外科,2012,19:388-390.
10.Campagnolo AM,Priston J,Thoen RH,et al.Laryngopharyngeal reflux:diagnosis,treatment,and latest research.Int Arch Otorhinolaryngol,2014,18:184-191.